Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
63 hedge funds and large institutions have $52.9M invested in Adamas Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 11 closing their positions.
58% more capital invested
Capital invested by funds: $33.5M → $52.9M (+$19.4M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
3% more funds holding
Funds holding: 61 → 63 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
52% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.04M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.59M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.27M |
| 4 |
Two Sigma Investments
New York
|
+$538K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$396K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.22M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.08M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$945K |
| 4 |
BOS
Bingham Osborn & Scarborough
San Francisco,
California
|
-$533K |
| 5 |
Jane Street
New York
|
-$445K |
ADMS Hedge Fund Activity: Q3 2020 in Review
63 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2020, worth a combined $52.9M — up 58% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ADMS positions and 11 closed out — a net gain of 2 holders — while 12 added to existing stakes and 25 trimmed.
The largest buyer was Opaleye Management, adding an estimated $2.04M. The largest seller was Emerald Mutual Fund Advisers Trust, cutting an estimated $1.22M.
- 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2020, up from 61 in Q2 2020.
- Funds reported $52.9M of Adamas Pharmaceuticals stock for Q3 2020, up 58% quarter-over-quarter.
- 13 funds opened new Adamas Pharmaceuticals positions in Q3 2020 and 11 closed out, a net change of +2 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2020 was Opaleye Management, an estimated $2.04M added.
- The largest Adamas Pharmaceuticals seller in Q3 2020 was Emerald Mutual Fund Advisers Trust, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2020.